The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)-Reference-Cited by-同舟云学术

The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)

Published:2021-07-22 Issue: Volume: Page:
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Woldemeskel Bezawit A¹,Karaba Andrew H¹,Garliss Caroline C¹,Beck Evan J²,Wang Kristy H¹,Laeyendecker Oliver²,Cox Andrea L¹,Blankson Joel N¹

Affiliation:

1. Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland, USA

2. Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland, USA

Abstract

Abstract Previous studies have shown that certain vaccines induce suboptimal responses in people living with human immunodeficiency virus (HIV, PLWH). However, responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have not been fully characterized in these patients. Here we show that the BNT162b2 vaccine induces robust immune responses comparable to responses in healthy donors.

Funder

Johns Hopkins COVID-19 Vaccine-related Research Fund

Johns Hopkins Center for AIDS Research

National Cancer Institute

Division of Intramural Research

National Institute Allergy and Infectious Diseases

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab648/39773101/ciab648.pdf